Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM

Chemist Develops Potential Drug to Treat Type 2 Diabetes Without Harsh Side Effects

Sunday, July 12, 2020, By Dan Bernardi
Share
BioInspiredCollege of Arts and SciencesfacultyResearch and CreativeSTEM
head shot

Robert P. Doyle

Robert P. Doyle, the Laura J. and L. Douglas Meredith Professor in the Department of Chemistry in the College of Arts and Sciences and adjunct associate professor of medicine at SUNY Upstate Medical University, has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting and, in select cases, undesired weight loss. His research article, “Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,” has been published in the prestigious journal Cell Reports.

A common group of drugs used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do lower blood sugar levels in diabetic patients, their side effects include nausea, vomiting and weight loss.

Through a grant from the National Institutes of Health (NIH), Doyle and his team found a way to combine two molecules into a new substance that so far seems to lower blood sugar without those undesired side effects.

In technical terms, the team developed a new area of bioconjugation—a chemical technique used to couple two molecules. By binding together exendin-4 (Ex4), an FDA-approved GLP-1R agonist, to dicyanocobinamide (Cbi), which is a small piece of the complex vitamin B12 molecule, they produced Cbi-Ex4 in a technique they call “corrination.”

Data collected from testing Cbi-Ex4 in the musk shrew (Suncus murinus), the mammal used in this study due to its ability to vomit (rodents and many mammals lack that ability), revealed beneficial effects as evidenced by improved blood sugar levels during glucose tolerance tests and a profound reduction in vomiting compared to Ex4. Importantly, no weight loss was noted, again in stark contrast to the currently approved GLP-1R agonist, making this new drug ideal for patients who require glucoregulation without affecting their body mass index (BMI) levels. This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer or HIV, where weight-loss is counter-indicated.

The next step in the development of this groundbreaking drug is to move it through the pre-clinical phase into phase I human studies. Doyle and his team have submitted a new grant proposal to the NIH to fund this effort.

Doyle’s research was conducted in collaboration with the labs of Matt Hayes, professor in the Department of Psychiatry, University of Pennsylvania, and Bart C. De Jonghe, professor in the Department of Biobehavioral Health Sciences, University of Pennsylvania.

  • Author

Dan Bernardi

  • Recent
  • Student Veteran Anthony Ruscitto Honored as a Tillman Scholar
    Friday, July 18, 2025, By John Boccacino
  • Bandier Students Explore Latin America’s Music Industry
    Thursday, July 17, 2025, By Keith Kobland
  • Architecture Students’ Project Selected for Royal Academy Exhibition
    Thursday, July 17, 2025, By Julie Sharkey
  • NSF I-Corps Semiconductor and Microelectronics Free Virtual Course Being Offered
    Wednesday, July 16, 2025, By Cristina Hatem
  • Jianshun ‘Jensen’ Zhang Named Interim Department Chair of Mechanical and Aerospace Engineering
    Wednesday, July 16, 2025, By Emma Ertinger

More In STEM

NSF I-Corps Semiconductor and Microelectronics Free Virtual Course Being Offered

University researchers with groundbreaking ideas in semiconductors, microelectronics or advanced materials are invited to apply for an entrepreneurship-focused hybrid course offered through the National Science Foundation (NSF) Innovation Corps (I-Corps) program. The free virtual course runs from Sept. 15 through…

Jianshun ‘Jensen’ Zhang Named Interim Department Chair of Mechanical and Aerospace Engineering

The College of Engineering and Computer Science (ECS) is excited to announce that Professor Jianshun “Jensen” Zhang has been appointed interim department chair of mechanical and aerospace engineering (MAE), as of July 1, 2025. Zhang serves as executive director of…

Star Scholar: Julia Fancher Earns Second Astronaut Scholarship for Stellar Research

Julia Fancher, a rising senior majoring in physics and mathematics in the College of Arts and Sciences (A&S), a logic minor in A&S and a member of the Renée Crown University Honors Program, has been renewed as an Astronaut Scholar for…

Traugott Professor of Mechanical and Aerospace Engineering Bing Dong to Present at Prestigious AI Conference

Professor Bing Dong was recently selected to lead a workshop on artificial intelligence (AI) at NeurIPS, the Conference and Workshop on Neural Information Processing Systems. Founded in 1987, NeurIPS is one of the most prestigious annual conferences dedicated to machine learning and AI research. Dong’s workshop…

6 A&S Physicists Awarded Breakthrough Prize

Our universe is dominated by matter and contains hardly any antimatter, a notion which still perplexes top scientists researching at CERN’s Large Hadron Collider. The Big Bang created equal amounts of matter and antimatter, but now nearly everything—solid, liquid, gas or plasma—is…

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2025 Syracuse University News. All Rights Reserved.